Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Stifel Maintains Hold on Atara Biotherapeutics, Lowers Price Target to $2.3

Author: Benzinga Newsdesk | April 01, 2024 10:55am
Stifel analyst Benjamin Burnett maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Hold and lowers the price target from $4.8 to $2.3.

Posted In: ATRA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist